1.1904
0.0504 (4.42%)
0.0504 (4.42%)
Upgrade to Real-Time
Regular Market
Volume | 89,367 |
|
|||||
News | - | ||||||
Day High | 1.22 | Low High |
|||||
Day Low | 1.1103 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Onconova Therapeutics Inc | ONTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.15 | 1.1103 | 1.22 | 1.14 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
317 | 89,367 | $ 1.17 | $ 104,485 | - | 0.62 - 2.04 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
11:24:34 | 1 | $ 1.23 | USD |
Onconova Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 24.91M | 20.93M | 20.83M | $ 226.00k | $ - | -0.97 | -1.40 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 200.00k | 3.10% |
Onconova Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ONTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.846 | 1.49 | 0.846 | 1.19 | 1,076,562 | 0.3444 | 40.71% |
1 Month | 0.73 | 1.49 | 0.6962 | 1.13 | 338,518 | 0.4604 | 63.07% |
3 Months | 0.71 | 1.49 | 0.62 | 1.01 | 175,986 | 0.4804 | 67.66% |
6 Months | 1.43 | 1.49 | 0.62 | 1.01 | 118,297 | -0.2396 | -16.76% |
1 Year | 1.84 | 2.04 | 0.62 | 1.27 | 124,276 | -0.6496 | -35.3% |
3 Years | 4.20 | 19.30 | 0.62 | 8.07 | 10,385,625 | -3.01 | -71.66% |
5 Years | 180.00 | 208.50 | 0.62 | 9.46 | 7,416,713 | -178.81 | -99.34% |
Onconova Therapeutics Description
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. |